BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities. (Q38919639)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

review article

1 reference

title

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Daniela Rizzo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Maria Amato

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Palma Maurizi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Riccardo Riccardi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

language of work or name

English

0 references

publication date

5 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

20 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

page(s)

1397-1405

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

Mutations of the BRAF gene in human cancer

20 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Recurrent BRAF mutations in Langerhans cell histiocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Profiling critical cancer gene mutations in clinical tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Pediatric low-grade gliomas and the need for new options for therapy: Why and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Brainstem ganglioglioma successfully treated with vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Pilomyxoid astrocytoma treated successfully with vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

To BRAF or not to BRAF: is that even a question anymore?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Analysis of dermatologic events in vemurafenib-treated patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Up-regulation of hERG K⁺ channels by B-RAF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Interactions between hERG and KCNQ1 α-subunits are mediated by their COOH termini and modulated by cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Trametinib-induced Left Ventricular Dysfunction in a Child With Relapsed Neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17425255.2016.1214710

10.1080/17425255.2016.1214710

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27494648%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference